In vivo pharmacology of the dopaminergic stabilizer pridopidine

European Journal of Pharmacology

Volumn 644, Issue 1-3, 2010, Pages 88-95

  Ponten, Henrik ^a   Kullingsjö, Johan ^a   Lagerkvist, Sören ^a   Martin, Peter ^b   Pettersson, Fredrik ^a   Sonesson, Clas ^a   Waters, Susanna ^a   Waters, Nicholas ^a  

^a NeuroSearch Sweden AB   (Sweden)

^b Vårdcentralen Lerum ^*  (Sweden)

Author keywords

ACR16; Dopamine; Dopaminergic stabilizer; Huntington's disease; Pharmacology; Pridopidine

Indexed keywords

4 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE HYDROCHLORIDE; ACR 16; CENTRAL NERVOUS SYSTEM AGENTS; DEXAMPHETAMINE; DIZOCILPINE; DOPA; GLUTAMIC ACID; HUNTEXIL; NORADRENALIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUNTINGTON CHOREA; HYPERACTIVITY; IMMOBILIZATION; IN VIVO STUDY; LOCOMOTION; MALE; MICRODIALYSIS; MOUSE; NEUROCHEMISTRY; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RAT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIHYDROXYPHENYLALANINE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICRODIALYSIS; MOTOR ACTIVITY; NOREPINEPHRINE; PIPERIDINES; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2;

EID: 77955772400     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.07.023     Document Type: Article

References (48)

1. Alexander G.E., Delong M.R., Strick P.L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 1986, 9:357-381.
2. Carlsson A. Focusing on dopaminergic stabilzers and 5HT 2A receptor antagonists. Curr. Opin. CPNS. Investigat. Drugs 2000, 2:22-24.
3. Carlsson A., Carlsson M.L. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues Clin. Neurosci. 2006, 8:137-142.
4. Croxtall J.D., Scott L.J. Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder. CNS Drugs 2010, 24:245-262.
5. Dyhring T., Nielsen E.O., Sonesson C., Pettersson F., Karlsson J., Svensson P., Christophersen P., Waters N. The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties. Eur. J. Pharmacol. 2010, 628:19-26.
6. Feenstra M.G., Botterblom M.H., Mastenbroek S. Dopamine and noradrenaline efflux in the prefrontal cortex in the light and dark period: effects of novelty and handling and comparison to the nucleus accumbens. Neuroscience 2000, 100:741-748.
7. Frank S., Jankovic J. Advances in the pharmacological management of Huntington's disease. Drugs 2010, 70:561-571.
8. George S.R., Watanabe M., Di Paolo T., Falardeau P., Labrie F., Seeman P. The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology 1985, 117:690-697.
9. Hertel P., Fagerquist M.V., Svensson T.H. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 1999, 286:105-107.
10. Hirose T., Kikuchi T. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J. Med. Invest. 2005, 52(Suppl):284-290.
11. Johnson K.A., Conn P.J., Niswender C.M. Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol. Disord. Drug Targets 2009, 8:475-491.
12. Jordan S., Koprivica V., Dunn R., Tottori K., Kikuchi T., Altar C.A. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur. J. Pharmacol. 2004, 483:45-53.
13. Kim D.H., Maneen M.J., Stahl S.M. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics 2009, 6:78-85.
14. Krystal J.H., Perry E.B., Gueorguieva R., Belger A., Madonick S.H., Abi-Dargham A., Cooper T.B., Macdougall L., Abi-Saab W., D'Souza D.C. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch. Gen. Psychiatry 2005, 62:985-994.
15. Li X.M., Perry K.W., Wong D.T., Bymaster F.P. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berl) 1998, 136:153-161.
16. Loftis J.M., Janowsky A. The N-methyl-d-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol. Ther. 2003, 97:55-85.
17. Marcus M.M., Jardemark K.E., Wadenberg M.L., Langlois X., Hertel P., Svensson T.H. Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int. J. Neuropsychopharmacol. 2005, 8:315-327.
18. Marcus M.M., Wiker C., Franberg O., Konradsson-Geuken A., Langlois X., Jardemark K., Svensson T.H. Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. Int. J. Neuropsychopharmacol. 2009, 1-13. (Oct 19 [Epub ahead of print]).
19. Moghaddam B., Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 1990, 54:1755-1760.
20. Nakai S., Hirose T., Uwahodo Y., Imaoka T., Okazaki H., Miwa T., Nakai M., Yamada S., Dunn B., Burris K.D., Molinoff P.B., Tottori K., Altar C.A., Kikuchi T. Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. Eur. J. Pharmacol. 2003, 472:89-97.
21. Natesan S., Svensson K.A., Reckless G.E., Nobrega J.N., Barlow K.B., Johansson A.M., Kapur S. The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J. Pharmacol. Exp. Ther. 2006, 318:810-818.
22. Nilsson M., Carlsson A., Markinhuhta K.R., Sonesson C., Pettersson F., Gullme M., Carlsson M.L. The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:677-685.
23. Nutt D., Demyttenaere K., Janka Z., Aarre T., Bourin M., Canonico P.L., Carrasco J.L., Stahl S. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J. Psychopharmacol. 2007, 21:461-471.
24. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, New York, NY. second ed.
25. Pettersson F., Ponten H., Waters N., Waters S., Sonesson C. Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). J. Med. Chem. 2010, 53:2510-2520.
26. Pettersson F., Waters N., Waters E.S., Carlsson A., Sonesson C. The development of a new class of dopamine stabilizers. Poster presented at the Society for Neuroscience Annual Conference, Orlando, FL, USA 2002.
27. Ponten H., Sonniksen K., Abrahamsson T., Waters N., Gustafsson B., Hanse E., Groc L. Behavioral and neurochemical repercussions of hippocampal network activity blockade during the neonatal period. Brain Res. Dev. Brain Res. 2005, 155:81-86.
28. Rorick-Kehn L.M., Johnson B.G., Knitowski K.M., Salhoff C.R., Witkin J.M., Perry K.W., Griffey K.I., Tizzano J.P., Monn J.A., McKinzie D.L., Schoepp D.D. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) 2007, 193:121-136.
29. Rung J.P., Carlsson A., Markinhuhta K.R., Carlsson M.L. The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:833-839.
30. Rung J.P., Rung E., Helgeson L., Johansson A.M., Svensson K., Carlsson A., Carlsson M.L. Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization. J. Neural Transm. 2008, 115:899-908.
31. Seeman P., Tallerico T., Ko F. Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: implications for human positron emission tomography. Synapse 2003, 49:209-215.
32. Seeman P., Tokita K., Matsumoto M., Matsuo A., Sasamata M., Miyata K. The dopaminergic stabilizer ASP2314/ACR16 selectively interacts with D2(High) receptors. Synapse 2009, 63:930-934.
33. Semba J., Watanabe A., Kito S., Toru M. Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology 1995, 34:785-791.
34. Sonesson, C., Andersson, B., Waters, S., Waters, N., Tedroff, J., 2000. New modulators of dopamine neurotransmission. Patent application no. WO146145 A1.
35. Strange P.G. Antipsychotic drug action: antagonism, inverse agonism or partial agonism. Trends Pharmacol. Sci. 2008, 29:314-321.
36. Svensson T.H. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:1145-1158.
37. 2 receptors. Poster presented at the Society for Neuroscience Annual Conference, Chicago, IL, USA 2009.
38. Tadori Y., Kitagawa H., Forbes R.A., McQuade R.D., Stark A., Kikuchi T. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. Eur. J. Pharmacol. 2007, 574:103-111.
39. Tedroff J., Lindskov Krogh P., Buusman A., Rembratt A. Pridopidine (ACR16) in Huntington's disease: an update on the MermaiHD and HART studies. Poster presented at the World Congress on Huntington's Disease, Vancouver, Canada 2009.
40. Tedroff J., Sonesson C., Waters N., Waters E.S., Carlsson A. A pilot study of the novel dopamine stabilizer ACR16 in advanced Parkinson's disease. Mov. Disord. 2004, 19:S201.
41. Tekin S., Cummings J.L. Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J. Psychosom. Res. 2002, 53:647-654.
42. Waters N., Carlsson A., Carlsson M., Martin P., Tedroff J., Kullingsjö J., Pettersson F., Sonesson C., Waters E.S. Pharmacology of ACR16, a dopamine stabilizer. Poster presented at the Society for Neuroscience Annual Conference, Orlando, FL, USA 2002.
43. Waters N., Lagerkvist S., Lofberg L., Piercey M., Carlsson A. The dopamine D3 receptor and autoreceptor preferring antagonists (+)-AJ76 and (+)-UH232; a microdialysis study. Eur. J. Pharmacol. 1993, 242:151-163.
44. Waters S., Pettersson F., Dyhring T., Sonesson C., Tedroff J., Waters N., Pontén H. Pharmacology of the dopaminergic stabilizer pridopidine (ACR16). Clin. Genet. 2009, 76(Suppl 1):74. (Abstract D10).
45. Waters S., Pettersson F., Dyhring T., Sonesson C., Tedroff J., Waters N., Pontén H. Preclinical pharmacology and mode of action of the dopaminergic stabilizer ACR16. Poster presented at the 4th Annual Huntington's Disease Therapeutic Conference, Cannes, France 2009.
46. Westerink B.H., de Boer P., de Vries J.B., Kruse C.G., Long S.K. Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur. J. Pharmacol. 1998, 361:27-33.
47. Westerink B.H., Kawahara Y., De Boer P., Geels C., De Vries J.B., Wikstrom H.V., Van Kalkeren A., Van Vliet B., Kruse C.G., Long S.K. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur. J. Pharmacol. 2001, 412:127-138.
48. Westerink B.H., Korf J. Comparison of effects of drugs on dopamine metabolism in the substantia nigra and the corpus striatum of rat brain. Eur. J. Pharmacol. 1976, 40:131-136.